Improved Bulbar Function in Amyotrophic Lateral Sclerosis after Nuedexta (Dextromethorphan and Quinidine) Treatment
Journal of the Korean Neurological Association
;
: 171-173, 2019.
Article
in Korean
| WPRIM
| ID: wpr-766771
ABSTRACT
Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quinidine
/
United States Food and Drug Administration
/
Deglutition
/
Dextromethorphan
/
Amyotrophic Lateral Sclerosis
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Neurological Association
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS